The Near Future of Pulmonary Arterial Hypertension Development

MD Mag: What clinical progress will highlight PAH discussion at CHEST 2019?

Tapson: Any registry data we have, we like to take out as far as we can. If we have 1 or 2 years followed and get 3 or 4, it’s very important to be able to do that. In terms of new studies, we still have data coming out of the GRIPHON study—different sub studies that are being presented in published in abstract form and being published from this large file. We’re still seeing more of that.

Again, we’ll see the TRITON study data eventually, not quite yet, but eventually. So, many more things coming and a lot of them amount to how we can do in patients already on background therapy. It’s more challenging to see improvement for patients on 1 or 2 drugs already. We saw that in GRIPHON—it was fantastic, a third of the patients are on to background therapies and we still saw improvement. The rest are on a single background therapy, so being able to add a medication with different mechanism and keep pushing the envelope for it was really important.

I think we’ll hear more data, and that is big.

Leave a Reply

Your email address will not be published. Required fields are marked *